Kedar Dave

Kedar Dave is currently based in Seattle, WA and leads the CMC Biostatistics group supporting the Cell Therapy Franchise at Bristol Myers Squibb. He originally joined BMS (Syracuse, NY) in 2012 where he provided CMC Statistics support for BMS's Biologics programs from late phase development to post-marketing applications. In 2016 he joined Juno Therapeutics which later got acquired by Celgene, and rejoined BMS as a result of the Celgene-BMS integration in 2019. Prior to joining BMS, Kedar has worked at Dow Chemical and Genentech. Kedar holds a Ph.D. in Chemical Engineering from University of Maryland College Park. His areas of interest are Design and Analysis of Experiments, Multivariate data analysis, Data-driven Root-cause investigations and Statistical Process Control.